A next-generation sequencing analysis of circulating tumour DNA (ctDNA) from 442 patients with cancer of unknown primary (CUP) has revealed the presence of at least one detectable alteration in 79.9% of patients, of which 89.6% of alterations were potentially targetable through off-label use of FDA-approved

中文翻译：

---

靶向治疗：在CUP患者中鉴定出ctDNA

对442例原发性癌症未知（CUP）患者的循环肿瘤DNA（ctDNA）的下一代测序分析表明，在79.9％的患者中存在至少一种可检测到的改变，其中89.6％的改变可能通过靶向FDA批准的标签外使用